版权说明 帮助中心
首页 > 成果 > 详情

Serum zinc-α2-glycoprotein levels are elevated and correlated with thyroid hormone in newly diagnosed hyperthyroidism

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Xin-Hua Xiao;Xiao-Yan Qi;Jiao-Yang Li;Yi-Bing Wang;Ya-Di Wang;Zhe-Zhen Liao;Jing Yang;Li Ran;Ge-Bo Wen;Jiang-Hua Liu
作者机构:
[Xin-Hua Xiao; Xiao-Yan Qi; Jiao-Yang Li; Yi-Bing Wang; Ya-Di Wang; Zhe-Zhen Liao; Jing Yang; Li Ran; Ge-Bo Wen; Jiang-Hua Liu] The First Affiliated Hospital of University of South China
语种:
英文
期刊:
BMC Endocrine Disorders
年:
2019
卷:
19
期:
1
页码:
12-
机构署名:
本校为第一机构
摘要:
Zinc-α2-glycoprotein (ZAG) is a recently novel lipolytic adipokine implicated in regulation of glucose and lipid metabolism in many metabolic disorders. In vitro and animal studies suggest that thyroid hormones (TH) up-regulates ZAG production in hepatocytes. However, there is no data evaluating the possible relationship between ZAG and TH in a human model of hyperthyroidism. The objective of the present study is to assess the association of serum ZAG levels with TH and lipid profile in patients with hyperthyroidism before and after methimazole treatment. A total of 120 newly diagnosed overt hyperthyroidism and 122 healthy control subjects were recruited. Of them, 39 hyperthyroidism patients were assigned to receive methimazole treatment as follow-up study for 2 months. The clinical consequence showed that serum ZAG levels were elevated in patients with hyperthyroidism (P < 0.01). Adjust for age, gender and BMI, serum ZAG levels were positively related with serum free T3 (FT3), free T4 (FT4) levels and negatively correlated with serum total cholesterol (TC), low density lipoprotein cholesterol (LDLC) levels in hyperthyroidism subjects (all P < 0.01). After methimazole treatment, serum ZAG levels were decreased and the decline was associated with decreased FT3, FT4 and increased TC levels (all P < 0.001). We conclude that ZAG may be involved in the pathogenesis of lipid metabolism disorder in patients with hyperthyroidism. ChiCTR-ROC-17012943. Registered 11 October 2017, retrospectively registered.
参考文献:
Maji D. Hyperthyroidism. J Indian Med Assoc. 2006,104(10):563–4 566-7.
Song Y, Yao X, Ying H. Thyroid hormone action in metabolic regulation. Protein Cell. 2011,2:358–68.
Mashita K, Tarui S. Thyroid gland dysfunction and metabolic abnormalities, with special reference to abnormal lipid and glucose metabolism. Nihon Rinsho. 1980,38(3):1656–65.
Kokkinos S, Papazoglou D, Zisimopoulos A, Papanas N, Tiaka E, Antonoglou C, Maltezos E. Retinol binding Protein-4 and adiponectin levels in thyroid overt and subclinical dysfunction. Exp Clin Endocrinol Diabetes. 2016,124(2):87–92.
Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: a potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018,39:151–8.

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com